The effect of oestrogen and alendronate therapies on postmenopausal bone loss around osseointegrated titanium implants


Autoria(s): Giro, Gabriela; Coelho, Paulo G.; Rodrigues Pereira, Rosa Maria; Jorgetti, Vanda; Marcantonio, Elcio; Orrico, Silvana Regina Perez
Contribuinte(s)

Universidade Estadual Paulista (UNESP)

Data(s)

30/09/2013

20/05/2014

30/09/2013

20/05/2014

01/03/2011

Resumo

Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)

Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES)

ObjectivesThis study evaluated the influence of oestrogen deficiency and its therapies on bone tissue around osseointegrated implants.MethodsImplants were placed in 66 female rats tibiae. The animals were assigned into five groups: control (CTL), sham, ovariectomy (OVX), oestrogen (EST), and alendronate (ALE). While CTL was sacrificed 60 days after implant placement, other groups were subjected to ovariectomy or sham surgery according to group and euthanized after 90 days. Blood and urine samples were collected at sacrifice day for osteocalcin (OCN) and deoxypyridinoline (DPD) quantification. Densitometry of femur and lumbar vertebrae was performed in order to evaluate rats' skeletal impairment. Non-decalcified sections were referred to fluorescent and light microscopy for analyses of mineral apposition rate (MAR), eroded and osteoclastic surfaces, bone-to-implant contact (BIC), and bone area fraction occupancy (BAFO).ResultsResults from the OVX group showed significantly lower bone mineral density (BMD), BIC, BAFO, and MAR, while OCN, deoxipiridinoline, eroded surface and ostecoclastic surface were increased compared with the other groups of the study. ALE reduced OCN and DPD concentrations, MAR, osteoclastic and eroded surfaces, and no difference was in BIC and BAFO relative to SHAM. EST and CTL showed similar results to SHAM for measurements.ConclusionsOestrogen deficiency exerted a negative influence on bone tissue around implants, while oestrogen replacement therapy and alendronate were effective against its effects. Although alendronate therapy maintained the quantity of bone around implants, studies evaluating bone turnover kinetics are warranted.To cite this article:Giro G, Coelho PG, Pereira RMR, Jorgetti V, Marcantonio E Jr, Orrico SRP. The effect of oestrogen and alendronate therapies on postmenopausal bone loss around osseointegrated titanium implants.Clin. Oral Impl. Res. 22, 2011; 259-264.doi: 10.1111/j.1600-0501.2010.01989.x.

Formato

259-264

Identificador

http://dx.doi.org/10.1111/j.1600-0501.2010.01989.x

Clinical Oral Implants Research. Malden: Wiley-blackwell, v. 22, n. 3, p. 259-264, 2011.

0905-7161

http://hdl.handle.net/11449/15977

10.1111/j.1600-0501.2010.01989.x

WOS:000286891100004

Idioma(s)

eng

Publicador

Wiley-Blackwell

Relação

Clinical Oral Implants Research

Direitos

closedAccess

Palavras-Chave #alendronate #dental implants #oestrogen replacement therapy #osteoporosis #ovariectomy #rats
Tipo

info:eu-repo/semantics/article